Header Logo

Connection

Naoko Takebe to CA-19-9 Antigen

Back to Details
This is a "connection" page, showing publications Naoko Takebe has written about CA-19-9 Antigen.
Naoko Takebe
Connection Strength
0.036
CA-19-9 Antigen
  1. Dual Src and EGFR inhibition in combination with gemcitabine in advanced pancreatic cancer: phase I results : A phase I clinical trial. Invest New Drugs. 2018 06; 36(3):442-450.
    View in: PubMed
    Score: 0.036
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.